<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086133</url>
  </required_header>
  <id_info>
    <org_study_id>WU2021TBS</org_study_id>
    <nct_id>NCT05086133</nct_id>
  </id_info>
  <brief_title>cTBS on First-episode Drug Naive Patients With Schizophrenia</brief_title>
  <official_title>The Effect of cTBS on First-episode Drug Naive Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      cTBS is a promising novel intervention, which have strong potentials on moderating disease&#xD;
      syndrome, suck as verbal hallucination, and cognitive deficits in schizophrenia, as it has&#xD;
      been proved for the treatment of depression.&#xD;
&#xD;
      Therefore, the investigators designed this randomized controlled clinical trial to evaluate&#xD;
      the efficacy and safety of cTBS on prevention and treatment for cognitive deficiency,&#xD;
      psychotic syndrome and metabolic side-effects in drug-naive first episode individual with&#xD;
      schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      cTBS is a promising novel intervention, which have strong potentials on moderating disease&#xD;
      syndrome, suck as verbal hallucination, and cognitive deficits in schizophrenia, as it has&#xD;
      been proved for the treatment of depression.&#xD;
&#xD;
      Therefore, the investigators designed this randomized controlled clinical trial to evaluate&#xD;
      the efficacy and safety of cTBS on prevention and treatment for cognitive deficiency,&#xD;
      psychotic syndrome and metabolic side-effects in drug-naive first episode individual with&#xD;
      schizophrenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 group for intervention and 1 group for sham stimulation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participants will be randomized into experimental group or sham group by a predetermined randomization table. The participants, care provider, investigators and outcomes assessor will be blind to the grouping. The physician who perform the TMS intervention is not blind to the grouping.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Three-Factor Eating Questionnaire</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>min value 21, max value 84. The higher scores mean more unhealthy eating behavior.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MCCB</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>The MATRICSâ„¢ Consensus Cognitive Battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positive and negative syndrome scale</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>min score 30, max score 210. The higher score means more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>body mass index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting EEG</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>resting EEG (electroencephalogram) with eyes opened, eye closed and natural stimulation. The reEEG power spectra, functional connection will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>cTBS stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants randomized into experimental group will receive cTBS stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The participants randomized into experimental group will receive sham stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial magnetic stimulation</intervention_name>
    <description>transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.</description>
    <arm_group_label>cTBS stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham stimulation</intervention_name>
    <description>TMS coil vertical to the brain surface, with same protocol as cTBS</description>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with schizophrenia in accordance with DSM-5&#xD;
&#xD;
          -  The course of the disease less then 2 years&#xD;
&#xD;
          -  Accepting antipsychotics treatment for less then 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with other mental disease in accordance with DSM-5&#xD;
&#xD;
          -  Comorbid with other severe physiological disease&#xD;
&#xD;
          -  Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances&#xD;
             before&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Pregnant or lactating Contraindication to rTMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

